ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 08 December 8:00AM
Realtime Data

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
Real McCoy Real McCoy 45 seconds ago
Yeah of course all absolutely not.
nowwhat2 nowwhat2 1 minute ago
Blue Chip Meme Coins - ha - LoL - Oxymoron but whatever ; Alt Coin Season / Banana Zone

Just coins which've recieved a lot of internet publicity........

Where DOGE'll certainly is certainly one of them......'cuz it's also got Elon attached to it

Others in
DOGEUSD
devil dog 96 devil dog 96 2 minutes ago
If anyone missed the nice update we got from the company Thursday here it is. https://www.otcmarkets.com/otcapi/company/financial-report/418796/content


$ATMH
ATMH
FACT-MASTER FACT-MASTER 3 minutes ago
Look closely, Samsung's playbook ( Micron and Google too)

https://www.youtube.com/watch?v=sShMA85pv8M
NLST
Sideem Sideem 4 minutes ago
Some Saturday night fun...LOL.

Blackberry had an exhibit at https://natoedge24.nato.int/event/c76d41ec-3569-4910-a64a-b8e41a82eb2b/websitePage:1e47f05d-87b5-4c6d-bada-a5cc50cedb3a NATO EDGE 2024 . From their webpage, NATO Edge brings together decision-makers, innovators and vision
BB
4retire 4retire 4 minutes ago
Looking at RXRX. Saw you have a new position there as well. If this company succeeds in its effort to fast track beneficial treatments, new drug discoveries, running on NVDA A I will be a huge win for mankind. I would imagine successes will bring a lot of pharmaceuticals heading their way
NVDA RXRX
devil dog 96 devil dog 96 6 minutes ago
ATMH still has a micro 2.9 million unrestricted share count (float) the same micro unrestricted share count she had in early 2021. She is one of the lightest tickers in the OTC. New management has been protecting their float like no other company in the OTC. They just filed an S1 and will be fulling
ATMH
Bigfootbud Bigfootbud 8 minutes ago
2 Corinthians 4:16-18
“That is why we never give up. Though our bodies are dying, our spirits are being renewed every day. For our present troubles are small and won’t last very long. Yet they produce for us a glory that vastly outweighs them and will last forever! So, we don’t look at the t
Real McCoy Real McCoy 8 minutes ago
Hahahaha

Good standup stuff
devil dog 96 devil dog 96 9 minutes ago
Looks like the no proof scam theory clown🤡 show promo is back in full swing. The promoter clowns🤡 seem to be getting desperate with all their rambling we are seeing over the weekend. 😃 LMAO

https://investorshub.advfn.com/uimage/uploads/2024/6/21/jmismclown-show
ATMH
Zorax Zorax 9 minutes ago
That should read shitface set it up to give HIMSELF 75%.

Shitface set it up to give him 75% of everything and every coin that sold. All this while lying and driving bit coin to insane artificial levels.
rickstereo3333 rickstereo3333 10 minutes ago
Once again a clear demonstration of ZERO Market knowledge with the expected amateur analysis in tow.

All irrelevant until dilution actually occurs, but in the event it does, the -ve effects could be lessened IF the available shares are utilized for purchasing assets and/or merger act
SNPW
Cabocat1 Cabocat1 13 minutes ago
I've been gone over a year and I guess things have really changed here. Is anybody buying this down here?
SHWZ
Phantom Lord Phantom Lord 13 minutes ago
That's just the number the company provided. It's irrelevant now anyways since the trial was terminated
MRKR
bigstocksnbonds bigstocksnbonds 20 minutes ago
YW! Congrats on All those post holes dug out WONDERFUL JOB!!!!
DP1011 DP1011 20 minutes ago
.50 in sight. This is looking pretty good. 👍 🙌
DOGEUSD
Snake River Dog Snake River Dog 21 minutes ago
.0001 Stock That Could Bounce!! Higher Then HMBL!! did at .0046 by next year march 2025 if not sooner. Just found out something interesting!! On this stock (NAFS .0001) But just take my word for a grain of salt!! and do your own DD!! I put some good money down on this One!! and could be wrong. Your
HMBL NAFS
CorsairNavigator20 CorsairNavigator20 23 minutes ago
Personally I think 25M is too low for 160 patients. You will need quite a bit of support teams such as CROs, data review, analysis, more analysis and analysis and/or additional studies in case you get the odd one or two patients that fall out of your guidelines. You have a team of 8 people in Mr
MRKR
OMOLIVES OMOLIVES 23 minutes ago
I think he will be fine. He's out man...I guarantee it. He should be dumping all of his Preferred as well........
HMBL
FitForStocks FitForStocks 24 minutes ago
Same been accumulating at $.0003 the last few months and haven't sold one. Waiting to hear more from the company.
HMBL
boston127 boston127 24 minutes ago
You make a good point.

It is fine to express disappointment with a company if you invested in it, but yelling LFG!!! on here daily doesn't make the price go up. No one liked the dip down, every day, but this is not a crying room.
IGPK
CC88Trade CC88Trade 25 minutes ago
Full on hater now aren’t you. Pretty sad fall you’ve taken.
SDRC
Elroy Jetson Elroy Jetson 26 minutes ago
Trump's nominated head of Social Security is very concerned about the low labor force participation rate among Americans 75 years of age an older.

Although the participation rate is slowly rising, they're badly letting down America's economy.

https://www.siliconinvestor
JJ8 JJ8 26 minutes ago
Fundstrats Tom Lee: NEW Nvidia Price Prediction - "Nvidia will hit $20 Trillion!"
NVDA

Your Recent History

Delayed Upgrade Clock